This trial is active, not recruiting.

Conditions uterine fibroids, polyps
Treatment myosure tissue removal system
Phase phase 4
Sponsor Hologic, Inc.
Start date November 2010
End date November 2012
Trial size 600 participants
Trial identifier NCT01369758, TMP 200905


The objective of this study is to demonstrate the safety and effectiveness of community gynecologist initiated treatment of intra-uterine polyps and submucosal fibroids with the MyoSure Hysteroscopic Tissue Removal System in a significantly sized patient population.

United States No locations recruiting
Other Countries No locations recruiting

Study Design

Endpoint classification safety/efficacy study
Intervention model single group assignment
Masking open label
Primary purpose treatment
Subjects with intrauterine fibroids and/or polyps will undergo intrauterine pathology removal using the MyoSure Tissue Removal System; myomectomy procedure.
myosure tissue removal system Myomectomy procedure
The MyoSure Tissue Removal Device consists of a hand-held tissue removal device comprising a mechanical drive assembly connected to a drive cable and associated control box on one end, and a 3 mm shaft on the other end of the device. The shaft is approximately 12 cm long and equipped with an open channel that houses an oscillating blade. When the side channel is exposed to target tissue and the motor is activated, the oscillating blade will cut the tissue within the channel. Once cut, the tissue travels down the center of the 3mm shaft via suction coupled to the proximal end of the tissue removal device, and is trapped in a vacutainer bottle.

Primary Outcomes

Procedure Efficacy
time frame: 1 hour post treatment

Secondary Outcomes

Percentage of subjects that achieve 100% removal of target pathology
time frame: 1 hour post treatment

Eligibility Criteria

Female participants from 18 years up to 65 years old.

Inclusion Criteria: 1. Healthy female between 18 and 65 years of age 2. Subject must be able to understand, read and sign the study specific informed consent forms after the nature of the study has been fully explained to her 3. Subject is indicated for myomectomy or polypectomy 4. Subject exhibits intrauterine polyps and/or submucous myomas which meet one of the following criteria. In cases of subjects with multiple intrauterine pathology, classification is based as follows: - All polyps - All Type 0, Type 1 or Type 2 myomas ≤ 6 cm in diameter - Polyps plus Type 0, Type 1 or Type 2 myomas ≤6 cm in diameter Exclusion Criteria: 1. Subject is pregnant 2. Subject has an IUD at the time of the procedure. A subject may be enrolled in the study if the IUD is removed prior to the treatment procedure 3. Subject is taking an anticoagulant or antiplatelet medication other than low dose aspirin 4. Active pelvic inflammatory disease or pelvic/vaginal infection 5. Subject has a known or suspected coagulopathy or bleeding disorder 6. Subject has a history of disease which increases the risk for fluid overload (i.e. significant cardiac, hepatic, or renal dysfunction) 7. Subject has other co-morbid condition(s) that, in the opinion of the Investigator, could limit the subject's ability to participate in the study or impact the scientific integrity of the study

Additional Information

Official title MyoSure Hysteroscopic Tissue Removal System Registry Study
Principal investigator Edward Evantash
Description Between 500 and 600 subjects will be enrolled in a prospective, multi-center registry study. Approximately 100 of these cases will be completed in an office setting, with the remaining 400-500 cases completed in a hospital outpatient or ambulatory surgery center. Subjects will undergo a hysteroscopic tissue removal procedure to remove intrauterine polyps and submucosal fibroids.
Trial information was received from ClinicalTrials.gov and was last updated in November 2012.
Information provided to ClinicalTrials.gov by Hologic, Inc..